 |
Alemtuzumab
Product Approval Information - Licensing Action
Proper name: Alemtuzumab
Tradename: Campath
Manufacturer: Millennium and ILEX Partners, LP, Cambridge, MA , License #1289
Indication for Use: Treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy
Approval Date: 5/7/2001
Type of submission: Biologics license application
Approval Letter
(PDF),
(Text)
Label
(PDF),
(Text)
Last Updated: 3/5/2001
 Back
to Top 
Back to Index
Date created: September 16, 2003 |
|
